On June 29, 2016 Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, reported that Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, has progressed its Sym015 clinical candidate into a Phase 1 dose escalation trial in patients with solid tumors (Press release, Selexis, JUN 29, 2016, View Source!2016jun29-symphogen-cla/c1d4o [SID:1234513619]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Symphogen relied upon Selexis SGE (Selexis Genetic Elements) to facilitate the rapid, stable, and cost-effective expression of Sym015, which is a multi-targeting monoclonal antibody (MAb) mixture that targets the MET receptor.

The proto-oncogene c-MET, also called MET, has been recognized as an important mediator of uncontrolled growth of solid tumors. Research has shown that driver mutations that result in activation of the MET receptor tyrosine kinase (RTK) are associated with a wide range of human malignancies including cancers of the kidney, liver, stomach, breast, and brain.

Selexis SGEs are the foundation of the SUREtechnology Platform. SGEs are unique epigenetic DNA-based elements that control the dynamic organization of chromatin in all mammalian cells and allow for higher and more stable expression of recombinant proteins.

"We are pleased that the power of our Selexis Genetic Elements helped Symphogen efficiently produce their next-generation antibody candidate, Sym015, and move it rapidly into clinical development," said Igor Fisch, PhD, chief executive officer and chairman of Selexis. "The goal of our proprietary technology is to help our biopharmaceutical partners advance their discovery development programs into clinical trials and, ultimately, biologics manufacturing, offering patients new and improved treatment options."

In December 2014, Selexis and Symphogen A/S entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of recombinant MAb mixtures for the treatment of various cancers and infectious diseases. Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized MAb mixtures manufactured as single drug products.

On June 29, 2016 Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, reported that Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, has progressed its Sym015 clinical candidate into a Phase 1 dose escalation trial in patients with solid tumors (Press release, Selexis, JUN 29, 2016, View Source!2016jun29-symphogen-cla/c1d4o [SID:1234513619]). Symphogen relied upon Selexis SGE (Selexis Genetic Elements) to facilitate the rapid, stable, and cost-effective expression of Sym015, which is a multi-targeting monoclonal antibody (MAb) mixture that targets the MET receptor.

The proto-oncogene c-MET, also called MET, has been recognized as an important mediator of uncontrolled growth of solid tumors. Research has shown that driver mutations that result in activation of the MET receptor tyrosine kinase (RTK) are associated with a wide range of human malignancies including cancers of the kidney, liver, stomach, breast, and brain.

Selexis SGEs are the foundation of the SUREtechnology Platform. SGEs are unique epigenetic DNA-based elements that control the dynamic organization of chromatin in all mammalian cells and allow for higher and more stable expression of recombinant proteins.

“We are pleased that the power of our Selexis Genetic Elements helped Symphogen efficiently produce their next-generation antibody candidate, Sym015, and move it rapidly into clinical development,” said Igor Fisch, PhD, chief executive officer and chairman of Selexis. “The goal of our proprietary technology is to help our biopharmaceutical partners advance their discovery development programs into clinical trials and, ultimately, biologics manufacturing, offering patients new and improved treatment options.”

In December 2014, Selexis and Symphogen A/S entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of recombinant MAb mixtures for the treatment of various cancers and infectious diseases. Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized MAb mixtures manufactured as single drug products.